First publication describing use of CytoSorb during cardiac surgery

CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb^® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb^® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany.

The retrospective study, authored by Frank Born, et al., was recently published in the scientific journal "Kardiotechnik" and entitled, "Systemic Inflammatory Response Syndrome in Heart Surgery: New possibilities for treatment through the use of a cytokine adsorber during ECC?" The study compared the post-operative inflammatory response in 40 patients (20 control vs 20 CytoSorb® treated) undergoing high risk cardiac surgery involving hypothermic arrest and antegrade cerebral perfusion. In the treatment group, CytoSorb® was placed into a bypass blood circuit in the heart-lung machine and used intra-operatively (during surgery) to remove inflammatory mediators from the patients' blood. The control group did not utilize CytoSorb®.

The authors demonstrate that CytoSorb® usage results in a statistically significant decline in inflammatory mediators such as interleukin-6 (IL-6) and procalcitonin in the treatment group, compared to the control group, during the three days after the operation.

Dr. Robert Bartlett, MD, Chief Medical Officer of CytoSorbents and cardiothoracic surgeon stated, "Ahead of a prospective, randomized, pivotal cardiac surgery trial in the U.S., this paper supports the safety, feasibility, and scientific merit of using CytoSorb® intra-operatively during high risk cardiac surgery. As we have hypothesized, usage of CytoSorb® during the few hours of the surgical procedure appears to reduce the post-operative inflammatory response. This could be very important clinically, as patients who develop uncontrolled inflammation after cardiac surgery are highly prone to having dangerous complications such as multiple organ failure. This study gives us better visibility on what to expect in our own pending trial using CytoSorb® pre-emptively in this setting."